Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 402 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Tacrolimus/MMF Clear all

Conditions: Renal Transplantation
Interventions: TCD601, belatacept, ATG, TAC, MPA, Corticosteroids; Biological · Drug
Lead sponsor: ITB-Med LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 18
States / cities: Sacramento, California • San Francisco, California • Tampa, Florida + 15 more

Conditions: Heart Diseases, Heart Transplantation
Interventions: Tacrolimus, Cyclosporine, Mycophenolate mofetil, Methylprednisolone, Prednisone; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: Not listed
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hematologic Malignancies
Interventions: Drugs Cyclophosphamide, Fludarabine, Thiotepa, Tacrolimus, Mycophenolate mofetil; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 60 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 1 Diabetes, Hypoglycemia
Interventions: Allogeneic islets of Langerhans transplant; Biological
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Systemic Sclerosis
Interventions: RIC alloBMT w PTCy in refractory SSc; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Kidney Transplantation
Interventions: Belimumab; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 60 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Kidney; Complications, Allograft
Interventions: eculizumab; Drug
Lead sponsor: Sanjay Kulkarni; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions: Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy; Drug · Procedure · Other
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 18 Years to 66 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more

Conditions: Lung Transplant; Complications
Interventions: Tacrolimus Extended Release Oral Tablet [Envarsus], Tacrolimus, Mycophenolate Mofetil Hydrochloride, Prednisone, Azathioprine; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Malignant Neoplasm
Interventions: Total-body irradiation, Donor lymphocytes infusion (DLI), Cyclophosphamide, Allogeneic hematopoietic stem cell transplantation (HSCT), Tacrolimus, Mycophenolate mofetil; Radiation · Biological · Drug + 1 more
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Bone Marrow Failure, Hemoglobinopathies, Primary Immune Deficiency (PID), Autoimmune Cytopenia, Immune Dysregulation, Hemophagocytic Lymphohistiocytosis (HLH), Non Malignant Disorders
Interventions: ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs; Biological
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 6 Months to 50 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Myositis Associated Interstitial Lund Disease (MA-ILD)
Interventions: Nintedanib, Placebo, Standard of Care; Drug
Lead sponsor: Rohit Aggarwal, MD; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Denver, Colorado + 6 more

Conditions: Blood Stem Cell Transplant Failure, Leukemia, Hematologic Malignancies
Interventions: Cyclophosphamide, Fludarabine, Melphalan, Mesna, Rituximab, Stem Cell Transplantation, Thiotepa, Tacrolimus, Mycofenolate mofetil, G-CSF; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 75 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Failing Renal Allograft
Interventions: Belatacept, Calcineurin inhibitor therapy, Mycophenolate mofetil, prednisone; Drug
Lead sponsor: Andrew B Adams; Other
Eligibility: 18 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Abdominal Wall Defect
Interventions: abdominal wall transplantation, Immunosuppressive Agents; Procedure · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sickle Cell Disease, Sickle Cell Disorder, Hemoglobinopathies, Thalassemia, Anemia, Sickle Cell
Interventions: Cyclophosphamide, Pentostatin, Rabbit anti-thymocyte globulin, Tacrolimus, Mycophenolate mofetil, CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant; Drug · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Myeloablative Conditioning, HLA-mismatched Bone Marrow Transplantation, Graft Survival, Transplantation, Bone Marrow
Interventions: Cyclophosphamide, TBI, Busulfan, Unmanipulated Bone Marrow, Tacrolimus, Mycophenolate mofetil; Drug · Radiation · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 6 Months to 25 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 7
States / cities: Aurora, Colorado • Wilmington, Delaware • St. Petersburg, Florida + 4 more

Conditions: Kidney Diseases
Interventions: Sirolimus; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Kidney Transplantation
Interventions: Tacrolimus Modified Release (MR), Tacrolimus, cyclosporine microemulsion, mycophenolate mofetil; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 12 Years and older
Enrollment: 668 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 48
States / cities: Birmingham, Alabama • Mobile, Alabama • Loma Linda, California + 36 more

Conditions: Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders
Interventions: ATG dosing platform when combined with standard tacrolimus and mini methotrexate; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 75 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Liver Disease, Liver Transplantation
Interventions: Alemtuzumab, Cyclosporine, Mycophenolate mofetil, Tacrolimus, Liver transplant, Immunosuppression withdrawal; Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 8
States / cities: San Francisco, California • Denver, Colorado • Miami, Florida + 5 more

Conditions: Kidney Transplantation
Interventions: AEB071, Mycophenolic Acid; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: San Francisco, California • Cleveland, Ohio • Madison, Wisconsin

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 6 Months to 74 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 3
States / cities: Atlanta, Georgia • Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Kidney Transplant Rejection
Interventions: Extended-release tacrolimus, Immediate-release tacrolimus; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

A Study of TCD601 in de Novo Renal Transplant Recipients

Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens

Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes

RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis

CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients

Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Early Use of Long-acting Tacrolimus in Lung Transplant Recipients

Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases

Myositis Interstitial Lung Disease Nintedanib Trial

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

Belatacept Therapy for the Failing Renal Allograft

Vascularized Composite Allotransplantation for Treatment of Abdominal Wall Defects

A Blood Stem Cell Transplant for Sickle Cell Disease

Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies

Comparison of Sirolimus to Tacrolimus for Long Term Therapy in Kidney Transplant With no Steroids

Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients

Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant

Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients

Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients

Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients